Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes
NCT03762759Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- May 2019
- Primary completion
- May 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluciclovine f 18 in prostate adenocarcinoma (2 arms), sponsored by Emory University. Primary endpoint: Disease-Free Survival at 2 years. Started May 2019; status: active, not recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT03762759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762759.